{
    "clinical_study": {
        "@rank": "117829", 
        "brief_summary": {
            "textblock": "Omegaven is an intravenous fat emulsion (IFE) comprised of omega-3 fatty acids derived from\n      fish oil. It will be used in an open label compassionate use treatment protocol, as an\n      alternative to soybean oil (omega-6), as the sole IFE source of parenteral nutrition in an\n      effort to reduce and/or reverse parenteral nutrition associated liver disease. The study\n      will evaluate the safety and efficacy of Omegaven use in pediatric patients with PN\n      dependence and PNALD."
        }, 
        "brief_title": "Omegaven Expanded Access Protocol", 
        "condition": "Parenteral Nutrition Associated Liver Disease", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients will be PN dependent (unable to meet nutritional needs solely by enteral\n             nutrition) and are expected to require PN for at least another 30 days\n\n          -  Parenteral nutrition associated liver disease (PNALD) as defined as a direct\n             bilirubin of \u2265 2 mg/dL on the last two consecutive bilirubins while on PN.  Other\n             causes of liver disease should be excluded. A liver biopsy is not necessary for\n             treatment.\n\n          -  Failed standard/conventional therapies to prevent progression of PNALD.\n\n          -  Age newborn to 17 years of age\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Allergy to eggs and/or shellfish\n\n          -  Female who is pregnant or lactating\n\n          -  Severe hemorrhagic disorder\n\n          -  Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,\n              and alpha 1 anti-trypsin deficiency,)\n\n          -  18 years of age or older\n\n          -  Parent/legally authorized representative is unwilling to consent."
            }, 
            "gender": "Both", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "id_info": {
            "nct_id": "NCT02121769", 
            "org_study_id": "Omegaven Expanded Access"
        }, 
        "intervention": {
            "description": "10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.", 
            "intervention_name": "Omegaven", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "cholestasis", 
            "short bowel syndrome"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "email": "renolal@slhs.org", 
                "last_name": "Allyson Reynolds, NP", 
                "phone": "208-381-7370"
            }, 
            "facility": {
                "address": {
                    "city": "Boise", 
                    "country": "United States", 
                    "state": "Idaho", 
                    "zip": "83712"
                }, 
                "name": "St. Luke's Pediatric Surgery"
            }, 
            "investigator": {
                "last_name": "Sarah Hirsch, MD", 
                "role": "Principal Investigator"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Protocol for Patients With Parenteral Nutrition Associated Liver Disease (PNALD) to Access Parenteral Fish Oil (Omegaven\u00ae) - Omegaven IND 122375", 
        "overall_contact": {
            "email": "renolal@slhs.org", 
            "last_name": "Allyson Reynolds, NP", 
            "phone": "208-381-7370"
        }, 
        "overall_official": {
            "affiliation": "Pediatric Surgery", 
            "last_name": "Sarah Hirsch, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121769"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Luke's Health System, Boise, Idaho", 
            "investigator_full_name": "Sarah Hirsch, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "St. Luke\u2019s Health System, Boise, Idaho", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Luke\u2019s Health System, Boise, Idaho", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "April 2014"
    }
}